Management Strategies for Leptomeningeal Metastasis Following TKI Resistance

Overview

Leptomeningeal metastasis (LM) in EGFR-mutant lung cancer presents significant management challenges after TKI resistance. This review outlines multimodal treatment strategies and emphasizes the need for personalized approaches to improve patient outcomes.

Background

Leptomeningeal metastasis is a severe complication in patients with EGFR-mutant non-small cell lung cancer (NSCLC), often leading to poor prognosis and limited treatment options. The complexity of tumor staging and resistance mechanisms complicates management, necessitating a comprehensive understanding of therapeutic strategies. Current guidelines and emerging treatments aim to address these challenges and improve patient care.

Data Highlights

No specific numerical data provided in the source material.

Key Findings

• LM occurs in 3-5% of NSCLC cases and is associated with a dismal prognosis.
• Current treatment strategies for LM lack standardized protocols and require individualized approaches.
• Multimodal treatment options include targeted therapies, intrathecal drug administration, and radiotherapy.
• Emerging immunological strategies may offer additional therapeutic avenues for patients with LM.
• Improving CNS drug delivery and understanding resistance mechanisms are crucial for enhancing patient outcomes.

Clinical Implications

Healthcare professionals should adopt a multimodal approach when managing LM in EGFR-mutant NSCLC, considering patient-specific factors and tumor characteristics. Continuous evaluation of treatment efficacy and toxicity is essential to optimize therapeutic regimens.

Conclusion

The management of leptomeningeal metastasis following TKI resistance in EGFR-mutant lung cancer requires a tailored approach that integrates various treatment modalities. Ongoing research and collaboration among specialists will be vital to improve patient outcomes.

Related Resources & Content

1. Journal of Neuro-Oncology, 2014 -- A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer
2. Journal of Neuro-Oncology, 2025 -- Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single‑center retrospective study
3. Frontiers in Oncology, 2026 -- Case Report: Long-term survival with erlotinib for lung cancer with secondary leptomeningeal carcinomatosis
4. The ASCO Post, 2017 -- Bright Future for Osimertinib in EGFR T790M–Positive Lung Cancer
5. EANO-ESMO Clinical Practice Guideline -- Leptomeningeal metastasis from solid tumours
6. Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM) | Journal of Clinical Oncology
7. Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis: A Randomized Clinical Trial | Trials | JAMA Oncology
8. https://pure.eur.nl/ws/portalfiles/portal/116811042/Leptomeningeal_metastasis_from_solid_tumours_EANO_ESMO_Clinical_Practice_Guideline_for_diagnosis_treatment_and_follow-up.pdf
9. Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM) | Journal of Clinical Oncology
10. Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis: A Randomized Clinical Trial | Trials | JAMA Oncology | JAMA Network